cardiology
Arrhythmia

DOACS not all equal for prevention of stroke in atrial fibrillation


All DOACS have significant advantages over warfarin in older patients with atrial fibrillation in terms of reducing thromboembolic stroke, intracranial haemorrhage and all-cause mortality, a major comparison study has shown. Twice-daily DOACS dabigatran and apixaban were associated with a more favourable benefit-to-harm ration than the once-daily rivaroxaban, according to the retrospective new-user cohort study  conducted ...

Already a member?

Enter your email to keep reading.


OR